Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies in a research note issued on Thursday. They currently have a $177.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 23.86% from the company’s previous close.

Several other brokerages have also commented on JAZZ. Zacks Investment Research lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, June 27th. Cantor Fitzgerald reissued a “buy” rating and set a $197.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, June 27th. Cowen and Company reissued an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $182.72.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at 142.90 on Thursday. The company has a market capitalization of $8.58 billion, a P/E ratio of 21.59 and a beta of 1.10. The stock’s 50 day moving average price is $155.68 and its 200 day moving average price is $146.56. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 23.80%. The business had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same period last year, the company earned $2.67 EPS. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

WARNING: “Piper Jaffray Companies Reiterates Buy Rating for Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/piper-jaffray-companies-reiterates-buy-rating-for-jazz-pharmaceuticals-plc-jazz.html.

In other news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $152.98, for a total value of $30,596.00. Following the transaction, the executive vice president now owns 22,623 shares in the company, valued at approximately $3,460,866.54. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the completion of the transaction, the executive vice president now owns 32,322 shares in the company, valued at approximately $5,171,520. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,600 shares of company stock worth $1,641,720. Company insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Dimensional Fund Advisors LP increased its position in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock worth $16,082,000 after buying an additional 408 shares during the last quarter. Teachers Advisors LLC increased its position in Jazz Pharmaceuticals PLC by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 151,056 shares of the specialty pharmaceutical company’s stock worth $16,470,000 after buying an additional 13,119 shares during the last quarter. Bank of Montreal Can increased its position in Jazz Pharmaceuticals PLC by 171.4% in the first quarter. Bank of Montreal Can now owns 45,770 shares of the specialty pharmaceutical company’s stock worth $6,644,000 after buying an additional 28,904 shares during the last quarter. Gateway Investment Advisers LLC increased its position in Jazz Pharmaceuticals PLC by 13.0% in the first quarter. Gateway Investment Advisers LLC now owns 73,395 shares of the specialty pharmaceutical company’s stock worth $10,652,000 after buying an additional 8,418 shares during the last quarter. Finally, Capital Impact Advisors LLC increased its position in Jazz Pharmaceuticals PLC by 60.4% in the first quarter. Capital Impact Advisors LLC now owns 9,182 shares of the specialty pharmaceutical company’s stock worth $1,333,000 after buying an additional 3,456 shares during the last quarter. Institutional investors and hedge funds own 86.43% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.